cagrilintide novo nordisk announced on February 23, 2026, that its next-generation obesity drug CagriSema — one of the company's most critical pipeline assets — failed to outperform Eli Lilly's tirzepatide (Zepbound) in a Size:1000 mcg/ml - 10 ml x 3 protect from light Peptides in 2026, what
Pay in 4 interest-free payments of $7.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12